Patents by Inventor Beate Salvador
Beate Salvador has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10105355Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.Type: GrantFiled: August 3, 2015Date of Patent: October 23, 2018Assignee: BASF SEInventors: Martin Viertelhaus, Tiziana Chiodo, Beate Salvador, Marcus Vossen, Andreas Hafner, Tobias Hintermann, Walter Weishaar, Rolf Hellmann
-
Publication number: 20180230140Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.Type: ApplicationFiled: June 24, 2015Publication date: August 16, 2018Applicant: BASF SEInventors: Martin VIERTELHAUS, Tiziana CHIODO, Beate SALVADOR, Marcus VOSSEN, Andreas HAFNER, Tobias HINTERMANN, Martin SZELAGIEWICZ, Fritz BLATTER
-
Patent number: 10045998Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.Type: GrantFiled: December 9, 2014Date of Patent: August 14, 2018Assignee: BASF SEInventors: Tiziana Chiodo, Beate Salvador, Marcus Vossen, Andreas Hafner, Tobias Hintermann, Martin Szelagiewicz, Fritz Blatter, Martin Viertelhaus, Walter Weishaar
-
Patent number: 9884857Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.Type: GrantFiled: July 22, 2014Date of Patent: February 6, 2018Assignee: BASF SEInventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
-
Publication number: 20170216266Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: MARTIN VIERTELHAUS, Tiziana CHIODO, Beate SALVADOR, Marcus VOSSEN, Andreas HAFNER, Tobias HINTERMANN, Walter WEISHAAR, Rolf HELLMANN
-
Patent number: 9567317Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.Type: GrantFiled: October 16, 2013Date of Patent: February 14, 2017Assignee: BASF SEInventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Eva Roedel, Marcus Vossen
-
Patent number: 9556164Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.Type: GrantFiled: July 22, 2014Date of Patent: January 31, 2017Assignee: BASF SEInventors: Andreas Hafner, Fritz Blatter, Martin Szelagiewicz, Bernd Siebenhaar, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
-
Publication number: 20160303143Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.Type: ApplicationFiled: December 9, 2014Publication date: October 20, 2016Applicant: BASF SEInventors: Tiziana CHIODO, Beate SALVADOR, Marcus VOSSEN, Andreas HAFNER, Tobias HINTERMANN, Martin SZELAGIEWICZ, Fritz BLATTER, Martin VIERTELHAUS, Walter WEISHAAR
-
Publication number: 20160168142Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.Type: ApplicationFiled: July 22, 2014Publication date: June 16, 2016Inventors: Andreas HAFNER, Fritz BLATTER, Martin SZELAGIEWICZ, Bernd SIEBENHAAR, Tiziana CHIODO, Tobias HINTERMANN, Beate SALVADOR, Marcus VOSSER
-
Publication number: 20160168143Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The Invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the Invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.Type: ApplicationFiled: July 22, 2014Publication date: June 16, 2016Inventors: Andreas HAFNER, Fritz BLATTER, Martin SZELAGIEWICZ, Bernd SIEBENHAAR, Tiziana CHIODO, Tobias HINTERMANN, Beate SALVADOR, Marcus VOSSEN
-
Patent number: 9340536Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.Type: GrantFiled: June 13, 2013Date of Patent: May 17, 2016Assignee: BASF SEInventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Bernd Siebenhaar, Marcus Vossen
-
Patent number: 9290452Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.Type: GrantFiled: August 5, 2013Date of Patent: March 22, 2016Assignee: BASF SEInventors: Andreas Hafner, Fritz Blatter, Eva Roedel, Martin Szelagiewicz, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
-
Patent number: 9221789Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.Type: GrantFiled: June 18, 2013Date of Patent: December 29, 2015Assignee: BASF SEInventors: Tiziana Chiodo, Rolf Hellmann, Marcus Vossen, Beate Salvador, Andreas Hafner, Tobias Hintermann
-
Publication number: 20150246901Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.Type: ApplicationFiled: October 16, 2013Publication date: September 3, 2015Inventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Eva Roedel, Marcus Vossen
-
Publication number: 20150175544Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.Type: ApplicationFiled: August 5, 2013Publication date: June 25, 2015Applicant: BASF SEInventors: Andreas Hafner, Fritz Blatter, Eva Roedel, Martin Szelagiewicz, Tiziana Chiodo, Tobias Hintermann, Beate Salvador, Marcus Vossen
-
Publication number: 20150133463Abstract: Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(?)-menthol.Type: ApplicationFiled: June 13, 2013Publication date: May 14, 2015Applicant: BASF SEInventors: Tiziana Chiodo, Andreas Hafner, Tobias Hintermann, Beate Salvador, Martin Szelagiewicz, Fritz Blatter, Bernd Siebenhaar, Marcus Vossen
-
Publication number: 20150126520Abstract: Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.Type: ApplicationFiled: June 18, 2013Publication date: May 7, 2015Applicant: BASF SEInventors: Tiziana Chiodo, Rolf Hellmann, Marcus Vossen, Beate Salvador, Andreas Hafner, Tobias Hintermann